Standard of Care + Telisotuzumab Adizutecan + Osimertinib (Osi) + Cisplatin + Carboplatin + Pemetrexed
Phase 2/3Recruiting 1 views this week 0 watching⚡ Active
Interest: 45/100
45
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Non-Squamous Non-Small Cell Lung Cancer
Conditions
Non-Squamous Non-Small Cell Lung Cancer
Trial Timeline
Aug 3, 2025 → Nov 1, 2036
NCT ID
NCT07005102About Standard of Care + Telisotuzumab Adizutecan + Osimertinib (Osi) + Cisplatin + Carboplatin + Pemetrexed
Standard of Care + Telisotuzumab Adizutecan + Osimertinib (Osi) + Cisplatin + Carboplatin + Pemetrexed is a phase 2/3 stage product being developed by AbbVie for Non-Squamous Non-Small Cell Lung Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07005102. Target conditions include Non-Squamous Non-Small Cell Lung Cancer.
What happened to similar drugs?
3 of 20 similar drugs in Non-Squamous Non-Small Cell Lung Cancer were approved
Approved (3) Terminated (1) Active (16)
❌Camrelizumab;Pemetrexed and Carboplatin; Famitinib; + Camrelizumab;Pemetrexed and Carboplatin;PlaceboJiangsu Hengrui MedicinePhase 3
Hype Score Breakdown
Clinical
15
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07005102 | Phase 2/3 | Recruiting |
Competing Products
20 competing products in Non-Squamous Non-Small Cell Lung Cancer